
    
      Epidemiological studies have shown inverse relation between enterolactone levels and
      cardiovascular mortality. Participants will be stratified from first phase (NCT03573414) and
      then randomly allocated to treatment or placebo. Outcomes are measured at baseline and after
      8 weeks post consumption.
    
  